ROKIT Genomics, a subsidiary of ROKIT Healthcare, stands at the forefront of genetic research by specializing in single-cell transcriptome analysis services. Distinguished as the sole company in Korea operating BD’s BD Rhapsody HT and 10x’s Chromium iX equipment, ROKIT Genomics provides a range of professional experimentation and analysis services.
Precision in Single Cell Isolation: The meticulous dissociation of tissues into single cells represents a critical phase in single-cell transcriptome analysis. ROKIT Genomics excels in ensuring a high ratio of pure, viable single cells, free from debris—a factor crucial for the quality of analysis data. It boasts a unique capability for high-level isolation of single cells from tissues, setting it apart from other service providers in Korea.
Comprehensive Experiments with 10x Genomics and BD’s Rhapsody HT: ROKIT Genomics utilizes 10x Genomics’ Chromium iX, the most widely-used single-cell transcriptome analysis platform. This equipment allows for diverse experiments, including mRNA expression analysis (GEX), repertoire analysis of TCR BCR, ATAC analysis of euchromatin, and multiome capability for combined GEX and ATAC. Additionally, BD’s Rhapsody HT, while having a narrower application scope compared to 10x Genomics, offers the advantage of analyzing up to 6 times more cells with a single reagent (10,000 cells).
Revolutionizing Cost and Bioinformatics Analysis: The groundbreaking pricing strategy employed by ROKIT Genomics reduces the cost of experiments significantly. Beyond equipment operation, the company distinguishes itself in bioinformatics analysis by providing not only custom analytics but also final images usable in research papers. This service is extended to all customers, setting ROKIT Genomics apart from others in the field.
Exponential Growth and Varied Clientele: Experiencing exponential growth since 2021, ROKIT Genomics has achieved a remarkable annual growth rate exceeding 150%, culminating in sales of approximately 4 billion won in 2023. The company boasts a diverse clientele, including prestigious institutions such as the National Institute of Health in Korea Disease Control and Prevention Agency, the Korea Institute of Oriental Medicine, and the Ministry of Food and Drug Safety.
Notably, the Korea Food and Drug Safety Evaluation Institute conducted a groundbreaking study, differentiating neurons from stem cells through direct conversion. This research revealed variations in action potential among neurons. ROKIT Genomics contributed by analyzing fibroblasts, stem cells, and precursor neuron cells at the single-cell level, elucidating the reasons behind normal and abnormal action potentials in neurons. The comprehensive findings from this study were published in Cells.
(Cells 2023, 12(24), 2818; https://doi.org/10.3390/cells12242818)
Contributions to COVID-19 Research: In response to the global pandemic, ROKIT Genomics actively contributes to COVID-19 research. Collaborating with the Vaccine Clinical Research Department of the National Institute of Health, the company conducts single-cell transcriptome analysis on the blood of vaccinated medical staff, unraveling cellular-level phenomena post-vaccination.
Innovations in 2024: Anticipating future advancements, ROKIT Genomics is introducing new technologies in 2024. Notably, the company has developed a method to produce RNA seq results from one cell. Through collaboration with a Korean infertility hospital, it examines the profile of various mRNAs in one cell, offering valuable insights for researchers working with limited samples.
With an eye on growth and innovation, ROKIT Genomics is not just an order-taking company. Having achieved sales of KRW 4 billion and an operating profit surplus in 2023, the company plans to conduct research and technology development in new areas using single-cell transcriptome technology. Focused on expanding into various infectious diseases and platform areas related to new drug development, ROKIT Genomics aims to become a specialized service provider by 2024.
In a groundbreaking development in the medical field, ROKIT Healthcare proudly reveals their recent achievement of outstanding A grades from two specialized evaluation agencies within the context of the technology assessment for special listing. This accomplishment is of particular significance within the KOSDAQ technology special listing system, where the strict requirement for A or BBB grades, or higher, from two designated professional evaluation agencies aligns with the guidelines established by the Korea Exchange.
At the heart of ROKIT Healthcare’s triumph lies their pioneering ‘Hyper-Personalized Organ Regeneration Platform,’ globally acknowledged as the world’s first innovative medical technology meticulously crafted for the regenerative treatment of previously considered incurable chronic diseases. This advanced platform seamlessly integrates artificial intelligence (AI), 3D bioprinting, and a single-use medical device kit, strategically positioned within hospital operating rooms.
The strategic integration aims to achieve remarkable cure rates and cost-effectiveness through the implementation of just-in-time organ regeneration technology. Notably, ROKIT Healthcare takes the lead in the medical market by forging connections between anti-aging supplements and the single-cell RNA sequencing business, offering a comprehensive approach to preventing, diagnosing, and managing chronic diseases.
The recent evaluation not only underscores the technological brilliance of ROKIT Healthcare’s hyper-personalized organ regeneration platform, developed with domestic expertise, but also emphasizes its robust market viability in the medical landscape. With these positive outcomes, the company is now poised for dynamic expansion, both domestically and internationally, marking a significant stride in advancing global healthcare through cutting-edge medical technology.
In a revolutionary turn of events, ROKIT Healthcare [“ROKIT” as follows] is ushering in a new era of medical innovation with its foray into the European market, following the attainment of CE approval. This significant development marks the beginning of an exciting chapter, with initial sales in Spain and upcoming contracts scheduled for various countries in Q1 2024.
CE Approval and Market Entry:
Secured in the latter half of 2023, the CE (Conformité Européenne) approval not only underscores ROKIT Healthcare’s dedication to quality and adherence to international standards but also serves as a crucial certification for selling products in European countries. This approval acts as a catalyst for the company’s active entry into the global market. In January, ROKIT initiated demonstrations in collaboration with PRIN S.A. in Spain, focusing on wounds like Venous Ulcer and Diabetic Foot Ulcer (DFU), signaling the beginning of the application of the organ regeneration platform within Europe.
Revolutionizing Treatment Methods:
The organ regeneration platform is poised to revolutionize conventional treatment methods, promising groundbreaking results for patients and representing a crucial step in this inaugural challenge within Europe. As a trailblazer in technology, ROKIT explores expansion into various therapeutic areas, anticipating upcoming contracts that will drive the company’s growth and open new horizons in medical innovation.
Balkan Expansion and Strategic Partnerships:
ROKIT Healthcare’s groundbreaking organ regeneration platform is set to extend its reach to seven Balkan countries, including Serbia, Croatia, Bosnia and Herzegovina, Albania, North Macedonia, Kosovo, and Montenegro. This strategic expansion aligns with the company’s unwavering commitment to providing innovative medical solutions across diverse regions. Discussions with a prominent Bulgarian company, boasting a staggering 1 billion in sales revenue, mark a significant milestone in ROKIT’s pursuit of global market penetration and strategic partnerships.
Innovations in Turkey:
Turkey is gearing up to embrace ROKIT’s organ regeneration platform, with plans to launch the innovative technology in January by installing it in one of the country’s well-known private hospitals. This momentous occasion signifies ROKIT’s ongoing commitment to introducing cutting-edge medical solutions to markets worldwide.
As ROKIT Healthcare expands its footprint across Europe and engages in discussions with key players, the groundbreaking organ regeneration platform continues to represent a beacon of innovation in the global medical landscape. With strategic partnerships, diverse market entries, and a commitment to advancing medical solutions, ROKIT is poised to leave an indelible mark on the future of healthcare.
In November 2023, ROKIT Healthcare (ROKIT) achieved a noteworthy milestone through the successful execution of two demonstrations showcasing the Cartilage Regeneration Platform in Paraguay. On a global scale, osteoarthritis (OA) presents a significant health challenge, impacting approximately 690 million individuals, constituting 22.9% of the population aged 40 and above. The estimated market size for OA treatment stands at $16.5 billion, with a Compound Annual Growth Rate (CAGR) of 9.4% for OA therapeutics market and 6% for knee replacement market, resulting in $8.28 billion and $8.27 billion, respectively.
ROKIT has already commercialized the Skin Regeneration Platform in Latin American countries including Paraguay in 2022. The Cartilage Regeneration Platform demonstrations conducted in Paraguay serve as a strategic initiative to advance the commercialization of this groundbreaking technology.
Dr. Cardone, leading the surgery, mentioned, “This new technology is a hope that can improve the quality of life for the patients” expressing anticipation for positive outcomes. Notably, the two patients subjected to the treatment exhibited substantial improvement in pain indices, as reflected in significant reductions in WOMAC and KOOS data at the 8-week post-surgery assessment.
Principal Investigator, Dr. Elias, reported “Pain was assessed using the Pain Visual Analog Scale (EVA), and two patients scored 2/10 and 1/10, respectively.” He added, “While there is an improvement in the perception of quality of life, it is still too early (8 weeks) to fully quantify. Nevertheless, the patient is progressing well under the supervision of a physiotherapist, pending the submission of the final report upon completing 30 sessions.”
The safety and efficacy of the Cartilage Regeneration Platform procedure in Paraguay will undergo meticulous tracking and observation over the course of a year, ensuring a thorough and sustained evaluation of its effectiveness.
This new technology is a hope that can improve the quality of life for the patients
– Dr. Cardone Guillermo, Director of Orthopedics, Instituto Universitario Hospital Italiano
In an impressive series of accomplishments, ROKIT Healthcare, a pioneer in advanced organ regeneration biotechnology, has garnered international recognition. From prominent exhibitions to accolades from esteemed organizations, the company is leaving a lasting mark in the global landscape of regenerative medicine. Let’s delve into the significant milestones showcasing the company’s commitment to innovation and its transformative impact on the field.
► ROKIT Healthcare’s Triumph at the ‘2023 Korea ICT Awards’
2023.12.13
On the 13th, ROKIT Healthcare, led by CEO Seok-Hwan You, announced its special award at the ‘2023 Korea ICT Awards,’ hosted by the Ministry of Science and ICT. Over the past decade, the company has transformed its independently developed AI, 3D bio-printing, and regenerative kits into a ‘Hyper-Personalized Organ Regeneration’ platform.
Achievements include European medical device certification CE MDR, winning the grand prize at the GSMA APAC Tech Challenge, and recognition as an ‘Innovative Medical Technology’ by the Ministry of Health and Welfare. CEO Seok-Hwan You emphasized the advanced nature of their organ regeneration platform technology, positioning it as a potential global gold standard in therapy. With approximately 170 patents and ongoing efforts for international commercialization, ROKIT Healthcare is gaining attention globally for its platforms in skin, cartilage, and kidney regeneration.
► ROKIT Healthcare’s ‘Kidney Regeneration Platform’ Recognized at GITEX 2023
2023.10.31
Under the leadership of CEO Seok-Hwan You, ROKIT Healthcare proudly unveiled its groundbreaking Kidney Regeneration platform, earning recognition as one of the distinguished ‘Strange Future Technologies’ selected by BBC Science Focus at GITEX 2023. This unveiling took place during the largest IT exhibition in the Middle East, showcasing the platform’s innovative approach powered by artificial intelligence (AI) and 3D bioprinting. The technology utilizes autologous fat extracellular matrix (ECM) to create regenerative patches with biological ink materials, addressing not only kidney regeneration but also demonstrating potential applications in skin and cartilage regeneration.
Moreover, the platform’s significance extends to its selection for a national advanced regenerative medicine project, engaging in collaborative research and development with Seoul National University College of Medicine and Seoul Asan Medical Center. Furthermore, the global impact of ROKIT Healthcare’s initiatives is underscored by the success of their skin regeneration technology, approved in around 60 countries and commercially available in approximately 30 countries. This recognition emphasizes the company’s commitment to advancing regenerative medicine on a global scale.
► GDIN Recognition for ROKIT Healthcare’s Global Expansion
2023.12.28
On the 28th, Rokit Healthcare proudly announced its recognition as an excellent company in 2023 by the ‘Global Digital Innovation Network (GDIN),’ adding to its prestigious achievements. This acknowledgment, coupled with awards such as the World GSMA M360 Asia Pacific M360 Grand Prize, highlights the company’s impact globally. The entity under the Ministry of Science and ICT actively supports the overseas expansion efforts of technology companies in the domestic digital sector. ROKIT Healthcare’s growing influence in the global market, attributed to increased contracts and robust sales performance, is evident. The company envisions further global expansion, aiming to bring innovative medical technologies to approximately 1.7 billion patients worldwide while concurrently reducing treatment costs. Positioned at the forefront of the global market, ROKIT Healthcare pioneersHyper-Personalized Organ Regeneration technology, integrating AI, bio-printing, and regenerative medicine technologies.
► Fostering Global Talents: ROKIT Healthcare Broadens Biotech Education with Dr. INVIVO EDU
2024. 01. .04
During the government financial support project performance festival on January 4th, ROKIT Healthcare, led by CEO Seok-Hwan You, received recognition as an outstanding new industry STAR company. Celebrated for commendable contributions to industry-academia cooperation, the company specializes in a personalized regenerative treatment platform based on 3D bioprinting technology.
In conjunction with this success, the company unveiled plans to extend the reach of its 3D bioprinting education platform, ‘Dr. INVIVO EDU.’ This practical initiative, utilizing cutting-edge biotechnology, allows students to expand their horizons, preparing them for future careers in the bio and medical fields. The program, incorporating practical training and patient-customized treatment protocols, aims to cultivate skilled professionals and contribute to the advancement of biotechnology.
ROKIT Healthcare’s journey is marked by triumphs in innovation, recognition, and global impact. From groundbreaking technologies in organ regeneration to accolades at prestigious awards, the company’s dedication to advancing regenerative medicine is evident. As it continues to push boundaries, ROKIT Healthcare’s influence extends beyond transforming medical treatments to shaping the future of biotech education. The company is poised to further its global footprint, offering innovative solutions and nurturing the next generation of talents in the bio and medical fields.
In a significant stride towards revolutionizing healthcare, distinguished professors specializing in medicine and bioengineering, spanning both national and international realms, have recently disclosed their expert viewpoints on a pioneering “Hyper-Personalized Organ Regeneration Platform.” This revolutionary platform harnesses the power of ROKIT Healthcare’s state-of-the-art convergence technology, seamlessly fusing artificial intelligence and 3D bioprinting. The convergence of these cutting-edge technologies presents a promising avenue for the advancement of personalized organ regeneration.
